Petrelintide: The Long-Acting Amylin Analog (2026 Update)

Petrelintide is the lead asset in Zealand Pharma's obesity-pharmacology program, distinguished from the rest of the late-stage pipeline by mechanism. Where most of the late-stage candidates are GLP-1-class agents (mono-, dual-, or triple-receptor), petrelintide is an amylin analog. Amylin is a separate pancreatic hormone with its own receptor system, partially overlapping with GLP-1 in physiologic effects but pharmacologically distinct.

This post covers what petrelintide is, what amylin pharmacology actually does, what late-stage trials have shown, where the regulatory state sits as of May 2026, and what petrelintide approval would mean in a prescribing landscape increasingly crowded with GLP-1-class compounds.

What petrelintide is

Petrelintide is a long-acting amylin analog developed by Zealand Pharma. The relevant properties:

1. Amylin agonist. Activates the amylin receptor, distinct from the GLP-1, GIP, and glucagon receptors that the GLP-1-class compounds target. Amylin is co-secreted with insulin from pancreatic beta cells in physiologic glucose responses.
2. Long-acting. Engineered for once-weekly subcutaneous administration, comparable to weekly GLP-1 dosing schedules.
3. Monotherapy positioning. The phase 3 program studies petrelintide as a standalone agent in obesity. This contrasts with the other notable amylin analog, cagrilintide (Novo Nordisk), which is primarily studied in fixed-dose combination with semaglutide rather than as a monotherapy.

The mechanistic premise of amylin agonism for weight management:

• Slowed gastric emptying. Similar in direction to GLP-1, though through a different receptor pathway.
• Reduced glucagon secretion. Amylin suppresses post-prandial glucagon, contributing to glycemic control.
• Central satiety signaling. Amylin acts on hindbrain pathways to produce satiety, partially overlapping with GLP-1's central effects but through different neuronal circuits.

The pharmacology is described as complementary to GLP-1 rather than redundant. That framing is supported by combination data — semaglutide plus cagrilintide produces stronger weight loss than semaglutide alone — but it is not the only possible positioning. Petrelintide's monotherapy program tests whether amylin agonism alone, without GLP-1 stacking, produces clinically meaningful weight loss with a distinct tolerability profile.

Why amylin matters in a GLP-1-dominated landscape

The GLP-1 class has had a remarkable run. Approved compounds (semaglutide, tirzepatide, liraglutide) and late-stage candidates (retatrutide, MariTide, orforglipron, mazdutide, survodutide) have produced an unprecedented body of obesity-pharmacology data. The case for tracking amylin pharmacology in parallel rests on several observations:

Tolerability differentiation. GLP-1-class agents have a characteristic gastrointestinal-event profile — nausea, vomiting, diarrhea, particularly during dose escalation. Some patients tolerate it. Some do not. Amylin agonism has its own tolerability profile, qualitatively similar in some respects but different in others. Patients who discontinue GLP-1 therapy due to GI events may be candidates for amylin therapy.

Body composition signals. Phase 2 data on amylin analogs has suggested a fat-vs-lean composition signal that may differ from GLP-1 monotherapy. The relevant question is whether the weight that is lost is preferentially fat or whether it includes a substantial lean-mass component. Some amylin data suggests a more favorable fat-to-lean ratio. This signal needs phase 3 confirmation.

Mechanistic non-redundancy. A class of weight-management agents that acts through a different receptor pathway provides options for patients who do not respond well to GLP-1 or who plateau on GLP-1 therapy. Mechanistic diversity in the toolbox is intrinsically valuable.

Combination potential. If both petrelintide (amylin monotherapy) and an injectable GLP-1 are approved, a combination regimen — separate injections or eventual fixed-dose products — becomes a real possibility, expanding the range of clinically meaningful interventions.

The case is not that amylin is "better" than GLP-1. It is that amylin is meaningfully different, and meaningfully different mechanisms in a chronic-disease therapeutic class are valuable.

What the trials have shown

Petrelintide's clinical program has progressed through phase 2 with phase 3 in flight as of 2026.

Phase 2 obesity. Reported mean body-weight reductions in the 8% to 9% range at higher doses over the trial duration, against placebo of approximately 1%. The numbers are lower than injectable GLP-1 monotherapy in absolute terms; semaglutide and tirzepatide produce 15% to 22% in comparable trial durations. The phase 2 petrelintide signal is closer to first-generation GLP-1 (liraglutide, approximately 8%) than to second-generation injectables.

Tolerability. GI-event rates were lower than typical GLP-1-class profiles in the phase 2 readouts, consistent with the hypothesis that amylin agonism produces a different tolerability fingerprint. Whether this holds in larger, longer phase 3 trials is the key question.

Body composition. Phase 2 data suggested a fat-mass-dominant weight-loss signal, with a smaller lean-mass component than typically seen in GLP-1 monotherapy. The phase 3 program will provide definitive composition data through DEXA or comparable measurement.

Phase 3. Multiple phase 3 trials are in flight. Topline readouts are expected through 2026 and 2027.

The honest summary: petrelintide produces less raw weight loss than the GLP-1 leaders, with a different tolerability fingerprint and possibly more favorable body composition. Whether those trade-offs sort out in petrelintide's favor for the right patient population is what phase 3 is designed to answer.

Where the regulatory state stands as of May 2026

• Approval status: Not approved.
• Phase: Phase 3.
• FDA submission: Expected in the 2027 window depending on phase 3 readout timing.
• Earliest plausible decision: 2027 to 2028.
• Compounded versions: None. Petrelintide is a proprietary investigational compound; no legitimate compounded source exists.

This is the standard late-stage pipeline read. Petrelintide is not prescribable in 2026 through any legitimate channel.

How petrelintide compares to cagrilintide

Both petrelintide (Zealand Pharma) and cagrilintide (Novo Nordisk) are amylin analogs. The differentiation:

Cagrilintide is studied primarily as a combination component. The major Novo Nordisk program is the cagrilintide-plus-semaglutide fixed-dose combination, often referenced as CagriSema. Cagrilintide as monotherapy is not the lead positioning.

Petrelintide is studied as monotherapy. Zealand Pharma's lead phase 3 program tests petrelintide alone in obesity. Combination programs may follow, but the monotherapy data is the basis for initial submission.

Different molecules. Both are amylin analogs but with different molecular structures, different pharmacokinetic profiles, and different intended administration schedules.

For patients, the practical implication is that the post-2027 amylin landscape may include both monotherapy (petrelintide) and combination (CagriSema) options, with different positioning and different patient populations.

What petrelintide approval would change

If petrelintide is approved on the timelines suggested by current trial readouts:

1. A non-GLP-1 option in a GLP-1-dominated landscape. For patients who decline GLP-1 therapy, who do not tolerate it, or who plateau on it, petrelintide becomes the first non-GLP-1-class option in modern obesity pharmacology with a real efficacy signal. The therapeutic-class diversity is meaningful.
2. Monotherapy positioning. Cagrilintide's combination-only positioning meant patients access amylin agonism only as part of a GLP-1 regimen. Petrelintide changes that — amylin agonism becomes available without GLP-1.
3. Composition-focused prescribing. If the phase 3 body-composition data confirms favorable fat-to-lean ratios, petrelintide may be positioned for patients whose primary concern is body composition rather than maximum raw weight loss. Body recomposition rather than weight loss alone.
4. Combination regimen development. Approved petrelintide plus approved injectable GLP-1 creates the potential for off-label or eventually approved combination prescribing, which expands the range of clinically meaningful intervention options.

The competitive landscape is favorable for petrelintide in one specific sense: by 2027-2028, the GLP-1 class will be crowded. A mechanistically distinct option is intrinsically differentiated.

TelePeptide's prescribing posture

TelePeptide will offer petrelintide only after FDA approval and only through pharmacy channels that handle the approved branded manufactured product. Same posture as every other late-stage compound:

• No prescribing of investigational compounds. Petrelintide is in phase 3.
• No compounded versions. Petrelintide is patent-protected and not within compounding scope.
• Standard of care. Investigational compounds are not within current standard of care.

When petrelintide is approved, our prescribing model applies the same direct-pay transparent-pricing approach we use for currently approved compounds.

What to watch through 2026 and 2027

For patients tracking petrelintide:

1. Phase 3 obesity readouts. Mean weight loss, dose-response, body composition signal, tolerability profile. Topline readouts through 2026 and 2027.
2. Comparison data. Whether any phase 3 trial includes a head-to-head comparison with GLP-1 will substantially affect post-approval positioning. As of mid-2026, public information suggests primarily placebo-controlled trials.
3. FDA submission. Submission timing is the strongest signal of decision timing.
4. Combination program development. Whether Zealand Pharma develops fixed-dose petrelintide+GLP-1 combinations, or licensing partnerships do so, affects the post-2028 landscape.

Bottom line

Petrelintide is Zealand Pharma's long-acting amylin analog in late-stage clinical trials, with phase 2 weight-loss readouts of 8% to 9% and a tolerability fingerprint differentiated from GLP-1-class agents. It is not approved. The earliest plausible FDA decision is 2027 to 2028. As the first late-stage non-GLP-1-class obesity-pharmacology compound to approach approval, petrelintide will introduce meaningful mechanistic diversity to the prescribing landscape if the phase 3 data holds. Patients interested in amylin pharmacology should track the readouts and continue to base 2026 prescribing on currently approved compounds.